|Genomic characterization of metastatic breast cancers|
F Bertucci, CKY Ng, A Patsouris, N Droin, S Piscuoglio, N Carbuccia, ...
Nature 569 (7757), 560-564, 2019
|Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer|
L Martinet, I Garrido, T Filleron, S Le Guellec, E Bellard, JJ Fournie, ...
Cancer research 71 (17), 5678-5687, 2011
|Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)|
F André, T Bachelot, F Commo, M Campone, M Arnedos, V Dieras, ...
The lancet oncology 15 (3), 267-274, 2014
|Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.|
J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ...
Journal of clinical oncology: official journal of the American Society of …, 2015
|Mutational profile of metastatic breast cancers: a retrospective analysis|
C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ...
PLoS medicine 13 (12), e1002201, 2016
|Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry|
O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ...
Journal of Clinical Oncology 35 (13), 1403, 2017
|TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma|
F Bertrand, A Montfort, E Marcheteau, C Imbert, J Gilhodes, T Filleron, ...
Nature communications 8 (1), 2256, 2017
|Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort|
J Mazieres, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, ...
Annals of Oncology 27 (2), 281-286, 2016
|DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability|
F Lemée, V Bergoglio, A Fernandez-Vidal, A Machado-Silva, MJ Pillaire, ...
Proceedings of the National Academy of Sciences 107 (30), 13390-13395, 2010
|Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort|
O Gautschi, J Milia, B Cabarrou, MV Bluthgen, B Besse, EF Smit, J Wolf, ...
Journal of Thoracic Oncology 10 (10), 1451-1457, 2015
|Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in …|
S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ...
Annals of Oncology 26 (5), 873-879, 2015
|High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes|
L Martinet, S Le Guellec, T Filleron, L Lamant, N Meyer, P Rochaix, ...
Oncoimmunology 1 (6), 829-839, 2012
|Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network|
J Clin Oncol 35, 2008-2017, 2017
|CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics|
S Le Guellec, I Soubeyran, P Rochaix, T Filleron, A Neuville, I Hostein, ...
Modern Pathology 25 (12), 1551-1558, 2012
|Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study|
A Benlyazid, J Thariat, S Temam, O Malard, C Florescu, O Choussy, ...
Archives of Otolaryngology–Head & Neck Surgery 136 (12), 1219-1225, 2010
|Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO)|
T Valentin, A Le Cesne, I Ray-Coquard, A Italiano, G Decanter, E Bompas, ...
European journal of cancer 56, 77-84, 2016
|High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β–producing dendritic cells in human breast cancer|
L Martinet, T Filleron, S Le Guellec, P Rochaix, I Garrido, JP Girard
The Journal of Immunology 191 (4), 2001-2008, 2013
|CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients …|
A Gomez-Brouchet, C Illac, J Gilhodes, C Bouvier, S Aubert, ...
Oncoimmunology 6 (9), e1331193, 2017
|Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study|
M Luyckx, E Leblanc, T Filleron, P Morice, E Darai, JM Classe, G Ferron, ...
International Journal of Gynecologic Cancer 22 (8), 2012
|Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers|
A Drilon, JJ Lin, T Filleron, A Ni, J Milia, I Bergagnini, V Hatzoglou, ...
Journal of Thoracic Oncology 13 (10), 1595-1601, 2018